XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Rating of “Hold” from Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have earned a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $53.75.

XOMA has been the topic of a number of analyst reports. Lucid Cap Mkts lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Benchmark lowered shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. HC Wainwright lowered shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research report on Thursday, April 30th. Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th.

Institutional Trading of XOMA Royalty

Several large investors have recently made changes to their positions in XOMA. Dimensional Fund Advisors LP boosted its position in shares of XOMA Royalty by 207.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after acquiring an additional 90,025 shares in the last quarter. Opaleye Management Inc. boosted its position in shares of XOMA Royalty by 14.7% during the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares in the last quarter. Woodline Partners LP boosted its position in XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after buying an additional 29,715 shares in the last quarter. Vanguard Group Inc. boosted its position in XOMA Royalty by 4.6% in the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after buying an additional 29,298 shares in the last quarter. Finally, Occudo Quantitative Strategies LP acquired a new stake in XOMA Royalty in the second quarter valued at approximately $527,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Stock Performance

Shares of NASDAQ:XOMA opened at $42.15 on Monday. The company’s 50 day moving average price is $41.39 and its two-hundred day moving average price is $32.57. XOMA Royalty has a 12-month low of $22.29 and a 12-month high of $42.81. The firm has a market cap of $528.56 million, a PE ratio of 26.85 and a beta of 0.88. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The business had revenue of $12.32 million for the quarter, compared to analyst estimates of $13.91 million. Equities research analysts predict that XOMA Royalty will post 0.9 earnings per share for the current year.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.